RT Journal Article
T1 Growth hormone-loaded 3D printed silk fibroin-cellulose dressings for ischemic wounds
A1 Pita Vilar, María
A1 Caicedo Valdés, Diego
A1 Bravo López, Susana Belén
A1 Rodríguez-Moldes Rey, María Isabel
A1 Aznar Cervantes, Salvador D.
A1 Concheiro Nine, Ángel Joaquín
A1 Álvarez Lorenzo, Carmen
A1 Díaz Gómez, Luis
K1 3D printing
K1 Growth hormone
K1 Ischemic wounds healing
K1 Personalized dressings
K1 Proteomics
AB In this study, carboxymethyl cellulose-silk fibroin (CMC-SF) wound dressings loaded with growth hormone (GH) are developed for chronic wound care, particularly in diabetic ulcer regeneration. Designed with a porous and reproducible structure, the dressings enable rapid, localized GH release within 24 h and maintain high fluid absorption with minimal swelling, ensuring optimal conformity to the wound site. The inclusion of SF and GH significantly enhances cell proliferation, migration, and angiogenesis in vitro. The dressings also enable nontraumatic removal, as demonstrated in an in ovo model, supporting their suitability for clinical applications. In vivo testing in ischemic diabetic wounds shows accelerated tissue regeneration, reduced scarring, and improved healing quality. Proteomics and immunohistochemical analyses indicate that GH contributes to a more balanced inflammatory response, enhanced antioxidant activity and vascularization, and better regulation of tissue remodeling processes. Overall, the incorporation of GH within the CMC-SF dressings represents a promising and effective approach to support diabetic ulcer regeneration.
PB Wiley
SN 2192-2640
YR 2025
FD 2025-10-14
LK https://hdl.handle.net/10347/43678
UL https://hdl.handle.net/10347/43678
LA eng
NO M. Pita-Vilar, D. Caicedo-Valdés, S. B. Bravo, et al. “ Growth Hormone-Loaded 3D Printed Silk Fibroin-Cellulose Dressings for Ischemic Wounds.” Adv. Healthcare Mater. (2025): e02969. https://doi.org/10.1002/adhm.202502969
NO Xunta de Galicia for a predoctoral contract [ED481A-2023-164]. D.C-V. acknowledges IDIS collaboration for the development of the in vivo experiments
DS Minerva
RD 24 abr 2026